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Study
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Andréa Roseli Vançan Russo Horimoto1, Valéria Aparecida Costa Hong3, Luiz Aparecido Bortolotto3, 
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Abstract 
Background: Increased arterial stiffness predicts morbidity and mortality, independently of other cardiovascular risk 
factors, and glycemic control impairments are related to higher vascular stiffness. The aim of this study was to evalu‑
ate the association between HbA1c levels and increased arterial stiffness in a Brazilian rural population.
Methods: For this study were selected 1675 individuals (both genders and aged over 18 years) resident in the 
municipality of Baependi, a city located in the Southeast of Brazil. HbA1c levels were determined by HPLC. Pulse wave 
velocity (PWV) was measured with a non‑invasive automatic device (Complior).
Results: HbA1c levels were associated with an increased PWV. This was more relevant for the third tertile of age. 
In addition, logistic regression multivariate model including age, blood pressure, gender, BMI and fasting glucose 
showed that the elevation of a single unit percentage of HbA1c represented an increase of 54 % in the odds of 
increased arterial stiffness [OR 1.54 (95 % CI 1.01–2.17)]. Both, HbA1c and fasting glucose showed higher discrimina‑
tory power in the risk assessment for increased arterial stiffness in the non‑diabetic when compared to the diabetic 
group (AUC of HbA1c = 0.71 vs 0.57, p = 0.02; AUC of fasting glucose = 0.66 vs 0.45, p = 0.0007, respectively).
Conclusion: Our findings indicate that a increase in HbA1c levels is associated with increased arterial stiffness and 
that both, HbA1c and fasting glucose, presented higher discriminatory power in the risk assessment for increased 
arterial stiffness in the non‑diabetic group as compared to diabetic individuals.
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Background
Increased central arterial stiffness is an important 
determinant of cardiovascular disease (CVD) risk [1]. 
Epidemiological studies reported that increased arte-
rial stiffness predicts morbidity and mortality, inde-
pendently of other cardiovascular risk factors [1, 2]. 
Arterial stiffness measured through carotid-femoral 
pulse wave velocity (PWV)—a gold standard method—
has been associated with measures of subclinical CVD 
[3]. Moreover, several clinical studies have shown that 
the arterial stiffness is strongly associated with age, blood 
pressure [4] and various pathological processes such as 
hypertension, metabolic syndrome, chronic renal disease, 
and diabetes [5–8].
Glycated hemoglobin (HbA1c) is a marker of glycemic 
control that reflects the average blood glucose level over a 
period of 2–3 months. In addition, the American Diabetes 
Association published clinical guidelines in which HbA1c 
level was recommended as a diagnostic test for diabetes 
[9]. The association between HbA1c levels and coronary 
heart disease risk has been demonstrated previously [10] 
and more recently, some studies have shown the associa-
tion between HbA1c levels and arterial stiffness, measured 
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by PWV, in individuals with and without diabetes [11, 12] 
and in hemodialysis [13]. However, studies demonstrating 
the impact of HbA1c levels in the risk of increased arterial 
stiffness in the general population are sparse.
Based on this scenario and on the clinical applicabil-
ity of measurements of HbA1c and arterial stiffness, the 
aim of this study was to evaluate the association between 
HbA1c levels and increased arterial stiffness in a Brazil-
ian rural population.
Methods
Study population
The Baependi Heart Study is a genetic epidemiological study 
of cardiovascular disease risk factors, with a longitudinal 
design whose methodology has been previously described 
[14]. For this study we carried out a cross-sectional analysis 
of data collected in the second visit of the protocol (between 
2010 and 2013). In this study we selected 1675 individuals 
(both genders and aged 18–102  years) distributed in 109 
families resident in the municipality of Baependi, a city 
located in the Southeast of Brazil. The study protocol was 
approved by the ethics committee of the Hospital das Clíni-
cas, University of São Paulo, Brazil, and each subject pro-
vided informed written consent before participation.
Anthropometrical Investigations
Anthropometric parameters were measured accord-
ing to a standard protocol [14]. Height was measured in 
centimeters and weight in kilograms using a calibrated 
digital balance. Body mass index (BMI) was calculated as 
body weight (kg) divided by height squared (m2).
Blood pressure measurements
Blood pressure was measured using a standard digital 
sphygmomanometer (OMRON, Brazil) on the left arm 
after 5 min rest, in the sitting position. Systolic (SBP) and 
diastolic blood pressures (DBP) were calculated from 
three readings (mean value of all measurements), with a 
minimal interval of 3  min [14]. Pulse pressure (PP) was 
calculated as difference between SBP and DBP. The mean 
blood pressure (MBP) was calculated  as  DBP  plus  one-
third  PP. Hypertension was defined as mean SBP 
≥140 mmHg and/or DBP ≥90 mmHg and/or antihyper-
tensive drug use [15].
Glucose and HbA1c measurements
Fasting glucose were evaluated by standard techniques 
in 12-h fasting blood samples [16]. HbA1c levels were 
determined by high-performance liquid chromatogra-
phy (HPLC) (National Glycohemoglobin Standardization 
Program, USA). Diabetes mellitus was diagnosed by the 
presence of fasting glucose ≥126 mg/dL, HbA1c ≥6.5 %, 
or antidiabetic drug use.
PWV determination
Carotid–femoral PWV was measured noninvasively by 
an experienced observer using the Complior SP® (Artech 
Medical, Pantin, France). PWV was measurement after 
each participant had rested for 10–15  min in a supine 
position. One measurement was made for each partici-
pant using as quality control values of tolerance inferior 
to 5  %. The carotid artery and femoral artery pressure 
waveforms were recorded by simultaneous assessment 
of the pulse waves in the right common carotid and 
femoral arteries as described [17]. The PWV values were 
obtained based on the direct carotid–femoral distance, 
the values were then standardized to the ‘real’ carotid–
femoral distance by multiplying by 0.8 according to 
recent recommendations [18]. Because this correction, 
increased arterial stiffness was defined as PWV ≥10 m/s 
[18].
Statistical analysis
Categorical variables were presented as percent-
age, while continuous variables were presented as 
mean ±  SD. Since there is a well established cutoff for 
PWV in the literature, we carried out univariate and 
multivariate logistic regression analysis to determinate 
the association between HbA1c and increased arte-
rial stiffness, setting PWV >10  m/s as dependent vari-
able, and age, MBP, gender, BMI and glucose fasting as 
predictor variables. Test for linear trend (Jonckheere–
Terpstra test) was performed by assigning median value 
for each tertile and treated as continuous variables. The 
receiver operating characteristic (ROC) curve was built 
and the area under ROC curve (AUC) was used to meas-
ure the discriminatory power in the risk assessment for 
increased arterial stiffness. Areas under the ROC curves 
between the markers were compared using a parametric 
method, with GraphROC for Windows software [19]. 
Pearson correlation coefficients were used to estimate 
associations between PWV and their confusion vari-
ables. Statistical analyses were carried out using SPSS 
(version 20) software (Chicago, IL, USA), with the level 
of significance set at 5 %.
Results
Demographic data of the study sample
Of the 1675 individuals, 151 (9.0 %) had increased arte-
rial stiffness. The distribution of gender between normal 
(PWV <10  m/s) and increased (PWV ≥10  m/s) arterial 
stiffness groups was similar. Hypertension and diabetes 
frequencies were higher in increased arterial stiffness 
individuals (Table 1). In addition, demographic and clini-
cal data such as age, BMI, SBP, DBP, MBP, PP, PWV, glu-
cose and HbA1c also were higher in increased arterial 
stiffness individuals (Table 1).
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Correlations between PWV and covariables
Pearson correlation coefficients are summarized in 
Table 2. Age and MBP were the variables that showed the 
highest correlations with PWV (r =  0.68 and r =  0.46, 
respectively). In addition, among the variables associ-
ated with glycemic control, HbA1c showed a higher cor-
relation with PWV when compared to fasting glucose 
(r = 0.34 vs r = 0.31, respectively).
Test for linear trend and association between HbA1c 
and increased arterial stiffness
HbA1c levels were associated with an increasing trend of 
PWV in a dose-dependent fashion. This was more pro-
nounced in the third tertile of age (p for trend =  0.02) 
(Fig.  1). In this analysis, the difference in mean PWV 
values between the highest and the lowest tertiles of age 
was 2.44 m/s.
The univariate logistic regression analysis showed that 
the elevation of a single unit percentage of HbA1c rep-
resented an increase of 119  % in the odds of increased 
arterial stiffness [OR 2.19 (95  % CI 1.81–2.65)]. In the 
multivariate model including age, MBP, gender, BMI and 
fasting glucose, the elevation of a single unit percentage 
of HbA1c represented an increase of 54 % in the odds of 
increased arterial stiffness [OR 1.54 (95 % CI 1.01–2.17)] 
(Table 3).
Area under ROC curve of HbA1c and fasting glucose in the 
diabetic and non‑diabetic group
In both, diabetic and non-diabetic groups, the discrimi-
natory powers of HbA1c and fasting glucose in the risk 
assessment for increased arterial stiffness were not differ-
ent (AUC = 0.71 vs 0.66, p = 0.29; AUC = 0.57 vs 0.45, 
p  =  0.13, respectively). However, the AUC of HbA1c 
and AUC of fasting glucose were higher in the non-
diabetic when compared to the diabetic group (AUC 
of HbA1c = 0.71 vs 0.57, p = 0.02; AUC of fasting glu-
cose = 0.66 vs 0.45, p = 0.0007, respectively) (Fig. 2).
Discussion
The main finding of our study was the association 
between HbA1c with arterial stiffness in a Brazilian 
rural population in which the elevation of a single unit 
percentage of HbA1c represented an increase of 54 % in 
the odds of increased arterial stiffness even after adjust-
ing for confounding variables such as age, MBP, BMI, 
gender and fasting glucose. In addition, the HbA1c pre-
sented higher discriminatory power in the risk assess-
ment for increased arterial stiffness in the non-diabetic 
group.
Several studies have shown that HbA1c predicts car-
diovascular risk in people with [20] and without diabe-
tes [12]. Regarding the association of HbA1c with arterial 
stiffness, Teoh et  al. [21], studying 860 individuals from 
the Edinburgh Type 2 Diabetes Study, showed that PWV 
was associated with increasing HbA1c, only in the group 
Table 1 Characteristics of  subjects stratified by  increased 
arterial stiffness
Hypertension: systolic blood pressure ≥140 mmHg and/or diastolic blood 
pressure ≥90 mmHg or use of anti-hypertension drugs
Diabetes: fasting glucose ≥126 mg/dL and/or use of hypoglycemic drugs
Increased arterial stiffness: pulse wave velocity (PWV) ≥10 m/s
Continuous data are expressed as mean ± standard deviation
Categorical data are expressed as percentage
BMI body mass index, PWV pulse wave velocity, SBP systolic blood pressure, DBP 
diastolic blood pressure, MBP mean blood pressure, PP pulse pressure, HbA1c 
glycated hemoglobin
Characteristics PWV <10 m/s PWV ≥10 m/s p value
n 1524 151 *****
Age (years) 42.4 ± 15.3 67.4 ± 10.0 <0.001
Gender, male (%) 40.1 49.7 0.06
Diabetes (%) 5.0 30.5 <0.001
Hypertension (%) 32.9 84.1 <0.001
BMI (kg/m2) 25.7 ± 4.8 29.2 ± 29.1 <0.001
SBP (mmHg) 123.7 ± 16.7 142.9 ± 17.2 <0.001
DBP (mmHg) 75.8 ± 10.1 78.3 ± 10.5 0.005
PP (mmHg) 47.9 ± 16.3 64.8 ± 14.6 <0.001
MBP (mmHg) 91.4 ± 10.3 101.7 ± 12.4 <0.001
PWV (m/s) 7.4 ± 1.1 11.7 ± 1.6 <0.001
Fasting glucose (mg/dL) 91.1 ± 17.5 103.5 ± 26.1 <0.001
HbA1c (%) 5.6 ± 0.7 6.3 ± 1.1 <0.001
Table 2 Correlation matrix between age, BMI, fasting glucose, MBP, HbA1c and PWV
The level of significance was * p ≤ 0.001
PWV pulse wave velocity, BMI body mass index, MBP mean blood pressure, HbA1c glycated hemoglobin
Variables Age BMI Fasting glucose MBP HbA1c PWV
Age 1 0.19* 0.34* 0.33* 0.44* 0.68*
BMI 0.19* 1 0.24* 0.23* 0.17* 0.08*
Fasting glucose 0.34* 0.24* 1 0.15* 0.69* 0.31*
MBP 0.33* 0.23* 0.15* 1 0.16* 0.46*
HbA1c 0.44* 0.17* 0.69* 0.16* 1 0.35*
PWV 0.68* 0.08* 0.31* 0.46* 0.35* 1
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with mean HbA1c at least 7.6  %. Matsumae et  al. [13], 
studying 242 hemodialysis patients with and without 
diabetes, showed that HbA1c level was an independent 
determinant of arterial stiffness, measured by carotid-
femoral PWV, in both group. Corroborating such results, 
Liang et al. [12], studying 5098 Chinese individuals with-
out diabetes, showed that HbA1c levels were significantly 
associated with an increasing trend of carotid-femoral 
PWV in a dose-dependent fashion. In our study, HbA1c 
also was associated to carotid-femoral PWV in which 
the elevation of a single unit percentage of HbA1c repre-
sented an increase 54 % in the odds of increased arterial 
stiffness even after adjusting for confounding variables 
such as age, MBP, BMI, gender and fasting glucose. In 
addition, our study also showed that HbA1c levels were 
associated with an increasing trend of PWV in a dose-
dependent manner in individuals over 52 years (third ter-
tile of age). However, unlike the studies presented above, 
our sample is composed of individuals from the general 
population with a more heterogeneous composition of 
clinical conditions (healthy, diabetic, hypertensive, obese, 
etc.).
The use of HbA1c as glycemic control and cardiovascu-
lar risk marker is widely accepted in diabetic patients [20] 
and its clinical application in individuals without diabetes 
has never had great relevance. However, several studies 
have demonstrated the role of HbA1c in the cardiovas-
cular risk assessment of non-diabetic individuals [10, 12], 
which extends discussion about the use of HbA1c as a 
cardiovascular risk marker in individuals from the gen-
eral population. In our study, HbA1c showed higher 
nominally discriminatory power in the risk assessment 
for increased arterial stiffness in the non-diabetic when 
compared to the diabetic group (AUC of HbA1c in the 
non-diabetic higher than diabetic group). These data 
demonstrated that HbA1c can be an important determi-
nant in the risk assessment for increased arterial stiffness 
in non-diabetics individuals.
The association between excessive glucose expo-
sure, assessed by HbA1c, and arterial stiffness may be 
explained by several mechanisms such as elevated for-
mation of advanced glycation end products (AGEs) 
[22], which result in endothelial dysfunction due to the 
increased generation of reactive oxygen species (ROS), 
reduced bioavailability of nitric oxide (NO) and induc-
tion of inflammation [22–24]. All these mechanisms may 
contribute to development of cardiovascular disease.
Numerous studies have shown the superiority the 
HbA1c in relation to fasting glucose as a cardiovascular 
risk predictor variable [12, 24]. In our study, multivariate 
logistic regression analysis showed that HbA1c was asso-
ciated to an increased arterial stiffness odds even after 
adjustment for fasting glucose in the general population. 
In addition, despite the discriminatory power in the risk 
assessment for increased arterial stiffness of either indi-
ces (HbA1c and fasting glucose) being similar in both 
groups (diabetics and non-diabetics), the behavior of glu-
cose is different when dealing with non-diabetic as com-
pared to diabetic individuals (Fig. 2).
Our study has two drawbacks. First, it is a cross-sec-
tional analysis. Therefore, a causal relationship between 
arterial stiffness and HbA1c could not be established. 
Second, regarding measurement of HbA1c level, some 
factors such as kidney failure and uremia could influ-
ence the analysis [25]. However, as our study is based in 
a sample from the general population with low mean age, 
we think that these factors are not enough to modify our 
Fig. 1 Test for linear trend stratified by age tertile—HbA1c levels 
were associated with an increasing trend of PWV in a dose‑depend‑
ent fashion (p for trend <0.05)
Table 3 Association between HbA1c and increased arterial 
stiffness by logistic regression univariate and multivariate 
analysis in a Brazilian rural population
Increased arterial stiffness: pulse wave velocity (PWV) ≥10 m/s
Multivariate model: HbA1c, age, MBP, BMI, fasting glucose and gender
a Female group as reference
Variable Increased arterial stiffness
OR (95 % CI), p value
Univariate Multivariate
HbA1c 2.19 (1.81–2.65), <0.001 1.54 (1.01–2.17), 0.01
Age 1.13 (1.11–1.15), <0.001 1.14 (1.11–1.16), <0.001
MBP 1.08 (1.07–1.10), <0.001 1.07 (1.05–1.09), <0.001
BMI 1.02 (1.01–11.04), 0.04 1.01 (0.99–1.04), 0.28
Fasting glucose 1.02 (1.02–1.03), <0.001 0.99 (0.98–1.01), 0.54
Gender (female)a 1.47 (1.05–2.05), 0.03 1.01 (0.63–1.63), 0.95
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results due to the low prevalence of these two conditions 
in our cohort.
In summary, our findings indicate that the increase of 
HbA1c levels are associated with increased arterial stiff-
ness and that both, HbA1c and fasting glucose, presented 
higher discriminatory power in the risk assessment for 
increased arterial stiffness in the non-diabetic group. 
Therefore, we suggest that elevation of HbA1c levels, 
even within the normal range, could trigger vascular dys-
function in individuals of Brazilian rural population.
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